Zealand Pharma A/S (ZLDPF) to Release Quarterly Earnings on Thursday

Zealand Pharma A/S (OTCMKTS:ZLDPF) is anticipated to issue its results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($1.3651) per share and revenue of $2.8120 million for the quarter.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its quarterly earnings data on Thursday, February 19th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($1.34) by $0.53. The company had revenue of $10.79 million for the quarter, compared to analyst estimates of $19.69 million. Zealand Pharma A/S had a net margin of 70.06% and a return on equity of 48.10%. On average, analysts expect Zealand Pharma A/S to post $3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Zealand Pharma A/S Stock Performance

Shares of ZLDPF opened at $45.30 on Wednesday. The company has a current ratio of 23.57, a quick ratio of 23.57 and a debt-to-equity ratio of 0.02. The firm’s fifty day simple moving average is $46.89 and its two-hundred day simple moving average is $63.19. Zealand Pharma A/S has a 12 month low of $35.93 and a 12 month high of $83.12. The stock has a market capitalization of $3.24 billion, a P/E ratio of 3.31 and a beta of 0.87.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. William Blair reaffirmed a “market perform” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Finally, BNP Paribas Exane lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Three analysts have rated the stock with a Strong Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.